EMERALD — 1729333
Application number
1729333
Divisional(s)
Type(s)
Standard Characters
Category
Trademark
CIPO Status
ABANDONED SECTION 36
TM5 status
DEAD/APPLICATION/
Withdrawn/Abandoned
The owner of the trademark application withdrew (e.g. abandoned) the application and the application is no longer active.
Filed
2015-05-21
Applicant
Emerald Health Sciences Inc.
410-221 West Esplanade
North Vancouver
BRITISH COLUMBIA V7M3J3
Agent
VANTEK INTELLECTUAL PROPERTY LLP
(AKA D/B/A VANTEK IP LLP)
101 - 1001 West Broadway, Suite 380
Vancouver
BRITISH COLUMBIA V6H4E4
Documents
Index headings
- EMERALD
Goods (Nice class & Statement)
- 5
- (1) Protein powders for meal replacement; Botanical, herbal, nutraceutical, dietary and nutritional supplements for general health and well-being; botanical, herbal, nutraceutical, dietary and nutritional preparations and botanical, herbal, nutraceutical, dietary and nutritional substances containing plant extracts and plant-derived nutrients to reduce stress and fatigue, increase appetite, reduce anxiety, relax tension, mood enhancement and provide an improved sense of well-being; Pharmaceutical and nutraceutical preparations and pharmaceutical and nutraceutical substances containing plant extracts and plant derived ingredients for the treatment of metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, perioperative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), dup 15, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory connective tissue diseases, arthritis, neurodegenerative diseases, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, cerebral palsy, brain movement, ocular motility, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness and chemically induced sickness, bulimia, psychiatric disorders, schizophrenia, and drug, alcohol and nicotine abuse, autism, nausea, vomiting, loss of appetite, muscle tension, muscle spasms, epilepsy, glaucoma, arthritis,Parkinson's disease, gastrointestinal illness, anxiety, bi-polar disorder, depression, insomnia, and for topical treatment of skin inflammation, namely, eczema, psoriasis, atopic dermatitis, acne, rosacea, lichen planus, bullous pemphigold, vasculitis, granuloma annulare and erythroderma; medicinal herbs, medicinal oils, medicinal infusions for treating metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, peri-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), dup 15, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory connective tissue diseases, arthritis, neurodegenerative diseases, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, cerebral palsy, brain movement, ocular motility, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness and chemically induced sickness, bulimia, psychiatric disorders, schizophrenia, and drug, alcohol and nicotine abuse, autism, nausea, vomiting, loss of appetite, muscle tension, muscle spasms, epilepsy, glaucoma, arthritis, Parkinson's disease, gastrointestinal illness, anxiety, bi-polar disorder, depression, insomnia, and for topical treatment of skin inflammation, namely, eczema, psoriasis, atopic dermatitis, acne, rosacea, lichen planus, bullous pemphigold, vasculitis, granuloma annulare and erythroderma; appetite suppressants for medical purpose.
Services (Nice class & Statement)
- 35
- (1) Retail sale and sale of dietary and nutritional supplements, pharmaceutical preparations accessible online and by telephone, facsimile and mail order; online sale services in the field of dietary and nutritional supplements, pharmaceutical preparations; Distributorships in the field of dietary and nutritional supplements, pharmaceutical preparations.
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2015-05-21 | ||
| Created | 2015-05-22 | ||
| Formalized | 2015-05-29 | ||
| Amendment to Application | 2015-07-07 | Section 41(1)(a) - Owner Information / Voir Preuve au dossier/See evidence on File No. 1729333 | |
| Search Recorded | 2015-11-23 | ||
| Examiner's First Report | 2015-11-23 | 2016-05-23 | |
| Correspondence Created | 2016-08-10 | 2017-02-10 | |
| Extension of Time | 2017-02-15 | 2017-08-10 | Request Letter Date: 2017/02/08 |
| Extension of Time | 2017-08-30 | 2018-02-10 | Request Letter Date: 2017/07/21 |
| Rep for Service Changed | 2017-12-01 | From: 3802 To: 20629 | |
| Agent Changed | 2017-12-01 | From: 3802 To: 20629 | |
| Correspondence Created | 2018-01-17 | 2018-07-17 | |
| Correspondence Created | 2018-03-07 | 2018-09-07 | |
| Extension of Time | 2018-09-14 | 2019-03-07 | Request Letter Date: 2018/09/07 |
| Rep for Service Changed | 2019-06-10 | From: 20629 To: 22072 / Voir Preuve au dossier/See evidence on File No. 1729333 | |
| Agent Changed | 2019-06-10 | From: 20629 To: 22072 / Voir Preuve au dossier/See evidence on File No. 1729333 | |
| Division Recorded | 2020-02-14 | Division to 2011526(0) | |
| Extension of Time | 2020-02-14 | 2020-03-07 | Request Letter Date: 2019/08/14 |
| Agent Name Changed | 2020-07-29 | ||
| Extension of Time | 2020-09-24 | 2021-03-07 | Request Letter Date: 2020/09/03 |
| Extension of Time | 2021-02-24 | 2021-09-07 | Request Letter Date: 2021/02/10 |
| Extension of Time | 2021-08-09 | 2022-03-07 | Request Letter Date: 2021/07/21 |
| Default Notice Sent | 2022-03-29 | 2022-05-29 | |
| Abandoned - Section 36 | 2022-06-21 |